Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam Sells 2,275 Shares

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 2,275 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company’s stock, valued at $14,198,425.93. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Glaukos Price Performance

Shares of GKOS stock traded down $0.56 during mid-day trading on Friday, hitting $131.70. 646,196 shares of the stock traded hands, compared to its average volume of 569,709. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48. The firm has a market cap of $7.24 billion, a price-to-earnings ratio of -40.89 and a beta of 1.02. The company’s 50-day simple moving average is $129.70 and its 200-day simple moving average is $119.17. Glaukos Co. has a twelve month low of $59.22 and a twelve month high of $139.51.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The firm had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. During the same period in the previous year, the company earned ($0.55) earnings per share. Glaukos’s revenue was up 19.0% compared to the same quarter last year. As a group, equities research analysts expect that Glaukos Co. will post -2.16 earnings per share for the current year.

Hedge Funds Weigh In On Glaukos

Several hedge funds have recently made changes to their positions in GKOS. Assenagon Asset Management S.A. bought a new stake in Glaukos during the second quarter worth approximately $6,832,000. Natixis acquired a new position in shares of Glaukos in the 1st quarter worth $614,000. Vanguard Group Inc. raised its position in shares of Glaukos by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock worth $500,576,000 after purchasing an additional 72,159 shares during the period. UniSuper Management Pty Ltd acquired a new stake in shares of Glaukos during the first quarter worth $913,000. Finally, Duality Advisers LP purchased a new stake in shares of Glaukos during the first quarter valued at $3,476,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Ratings Changes

GKOS has been the subject of several recent research reports. Citigroup lowered shares of Glaukos from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $130.00 to $132.00 in a research report on Wednesday, July 10th. Stifel Nicolaus lifted their price target on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Morgan Stanley lifted their price objective on shares of Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Wells Fargo & Company upped their target price on shares of Glaukos from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Finally, BTIG Research lifted their price target on Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $130.45.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.